Sanchez-Duffhues G, Orlova V, Ten Dijke P. In Brief: Endothelial-to-mesenchymal transition. J Pathol. 2OL6 Feb;238(3) : 378-80.

Spiekerkoetter E, Tian X, Cai J, Hopper RK, Sudheendra D, Li CG, El-Bizri N, Sawada H, HaghighatR, Chan R, Haghighat L, de Jesus Perez V, Wang L, Reddy S, Zhao M, Bernstein D, Solow-Cordero DE, Beachy PA, Wandless TJ, Ten Dijke P, Rabinovitch M. FK506 activates BMPR2. rescues endothelial dysfunction, and reverses pulmonary hypertension.J Clin Invest. 2013 Aug;123(8):3600-13

Zhou 7, de Beer VJ, de Wijs-Meijler D, Bender SB, Hoekstra M, Laughlin MH, Duncker DJ, Merkus D. Pulmonary vasoconstrictor influence of endothelin in exercising swine depends critically on ohosphodiesterase 5 activity. Am J Physiol Lung Cell Mol Physiol. 2O14 Mar 1;306(5):L442-52

Bender SB, de Beer VJ, Tharp DL, van Deel ED, Bowles DK, Duncker DJ, Laughlin MH, Merkus DJ. Reduced contribution of endothelin to the regulation of systemic and pulmonary vascular tone in severe familial hypercholesterolaemia. Physiol. 2O14 Apr 1 5; 592(8) : t7 57 -69. doi : 10. 1 1 13/jphysiol. 20t3.267 351

Szulcek R, Happé CM, Rol N, Fontijn RD, Dickhoff C, Haftemink KJ, Grünberg K, Tu L, Timens W,Nossent GD, Paul MA, Leyen TA, Horrevoets AJ, de Man FS, Guignabe ÉC, Yu PB, Vonk-Noordegraaf A, van Nieuw Amerongen GP, Bogaard HJ. Delayed Microvascular Shear Adaptation in Pulmonary Arterial Hypertension. Role of Platelet Endothelial Cell Adhesion Molecule-1 Cleavage, Am J Respir Crit Care Med. 2016 Jun 15;193(12):1470-20.

Piekerkoetter E, Sung YK, Sudheendra D, Bill M, Aldred MA, van de Veerdonk MC, VonkNoordegraaf A, Long-Boyle J, Dash R, Yang PC, Lawrie A, Swift AJ, Rabinovitch M, Zamanian RT. Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2015 jul 15;792(2):254-7.

van de Veerdonk MC, Marcus JT, Westerhof N, de Man FS, Boonstra A, Heymans MW, BogaardHJ, Vonk Noordegraaf A. Signs of right ventricular deterioration in clinically stable patients with pulmonary arterial hypertension.Chest. 2015 Apr; L47 (4) : 1063-7 L

van Loon RL, Bartelds B, Wagener FA, Affara N, Mohaupt S, Wijnberg H, Pennings SW, Takens J, Berger RM. Erythropoietin Attenuates Pulmonary Vascular Remodelling in Experimental Pulmonary Arterial Hypertension through Interplay between Endothelial Progenitor Cells and Heme Oxygenase. Front Pediatr.2O15 Aug 28;3:71.

de Raaf MA, Kroeze Y, Middelman A, de Man FS, de Jong H, Vonk-Noordegraaf A, de Korte C,Voelkel NF, Homberg J, Bogaard HJ. Serotonin transporter is not required for the development of severe pulmonary hypertension in the Sugen hypoxia rat model. Am J Physiol Lung Cell Mol Physiol. 2O15 Nov 15;309(10):LtI64-73

Heinonen I, Sorop O, de Beer VJ, Duncker DJ, Merkus D. What can we learn about treating heart failure from the heart’s response to acute exercise? Focus on the coronary microcirculation. J Appl Physiol (1985). 2O15 Oct 15;119(B):934-43.

Kurakula K, Goumans MJ, Ten Dijke P.Regulatory RNAs controlling vascular (dys)function by affecting TGF-ß family signalling. EXCLI l. 2015 Jul 10;L4:832-50.

Ranchoux B, Antigny F, Rucker-Martin C, Hautefort A, Péchoux C, Bogaard HJ, Dorfmüller P,Remy S, Lecerf F, Planté S, Chat S, Fadel E, Houssaini A, Anegon I, Adnot S, Simonneau G,Humbert M, Cohen-Kaminsky S, Perros F. Endothelial-to-mesenchymal transition in pulmonary hypertension. Circulation. 2O15 Mar L7 L3I(LI): 1006-18

Sánchez-Duffhues G, de Vinuesa AG, Lindeman JH, Mulder-Stapel A, DeRuiter MC, Van

Munsteren C, Goumans MJ, Hierck BP, Ten Dijke P. SLUG is expressed in endothelial cells lacking primary cilia to promote cellular calcification. Arterioscler Thromb Vasc Biol. 2015 Mar;35(3):616-27.

Krenning G, Barauna VG, Krieger JE, Harmsen MC, Moonen JR. Endothelial Plasticity: Shifting Phenotypes through Force Feedback. Stem Cells Int. 2016;2016:9762959

van der Feen DE, Dickinson MG, Bartelds B, Borgdorft MA, Sietsma H, Lévy M, Berger RM. Egr-1 identifies neointimal remodeling and relates to progression in human pulmonary arterial hypertension. J Heart Lung Transplant. 2016 Apr;35(4):481-90.

Vonk Noordegraaf A, Groeneveldt JA, Bogaard HJ. Pulmonary hypertension. Eur Respir Rev. 2O16 Mar;25(139):4-tL

van der Bruggen CE, Happé CM, Goumans MJ, Bogaard HJ, Vonk Noordegraaf A, de Man FS. Response by van der Bruggen et al. to letter regarding article, Bone Morphogenetic Protein Receptor Type 2 Mutation in Pulmonary Arterial Hypertension: A View on the Right Ventricle. Circulation 2016

Hopper RK, Moonen JR, Diebold I, Cao A, Rhodes CJ, Tojais NF, Hennigs JK, Gu M, Wang L, Rabinovitch M. In Pulmonary Arterial Hypertension, Reduced BMPR2 Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and Its Target Slug. Circulation. 2016 May 3;133(18):1783-94

De Wijs-Meijler DP, Stam K, van Duin RW, Verzijl A, Reiss IK, Duncker DJ, Merkus D. Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine.J Vis Exp. 2O16 Feb 9;(108):e53772. doi: 10.3791/53772.

Dummer A, Poelma C, DeRuiter MC, Goumans MJ, Hierck BP.Measuring the primary cilium length: improved method for unbiased high-throughput analysis. Cilia. 2016 Feb 11;5:7. doi: 10.1186/s13630-0t6-0028-2.

Happé CM, de Raaf MA, Rol N, Schalij I, Vonk-Noordegraaf A, Westerhof N, Voelkel NF, de Man FS, Bogaard HJ. Pneumonectomy combined with SU5416 induces severe pulmonarv hypertension in rats. Am J Physiol Lung Cell Mol Physiol. 2O16 Jun 1;310(11):L1088-97

van der Bruggen CE, Happé CM, Dorfmüller P, Trip P, Spruijt OA, Rol N, Hoevenaars FP,Houweling AC, Girerd B, Marcus JT, Mercier O, Humbert M, Handoko ML, van der Velden J, Vonk Noordegraaf A, Bogaard HJ, Goumans MJ, de Man FS, van der Bruggen CE. Bone Morphogenetic Protein Receptor Type 2 Mutation in Pulmonary Arterial Hypertension: A View on the Right Ventricle. Circulation. 2016 May 3;133(18): L747-60

Happé CM, Szulcek R, Voelkel NF, Bogaard HJ. Reconciling paradigms of abnormal pulmonary blood flow and quasi-malignant cellular alterations in pulmonary arterial hypertension. Vascul Pharmacol. 2016 Jan 22. pü: S1537-1891(15)30102-6

Leberkühne LJ, Ploegstra MJ, Douwes JM, Bartelds B, Roofthooft MTR, Hillege HK, Berger RMF. Serially Measured Uric Acid Levels Predict Disease Severity and Outcome in Pediatric Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2016 (in press)

van der Feen DE, Weij M, Bartelds B, Berger RMF. Shunt Surgery, Right Heart Catheterization and Vascular Morphometry in a Rat model for Flow-induced Pulmonary Arterial Hypertension.  JoVE 2016 (accepted)

Rol N, Timmer EM, Faes TJ, Noordegraaf AV, Grünberg K, Bogaard HJ, Westerhof N.Vascular narrowing in pulmonary arterial hypertension is heterogeneous: rethinking resistance. Physiol Rep. 2017 Mar;5(6). pii: e13159. doi: 10.14814/phy2.13159.

Goumans MJ, Zwijsen A, Ten Dijke P, Bailly S. Bone Morphogenetic Proteins in Vascular Homeostasis and Disease. Cold Spring Harb Perspect Biol. 2017 Mar 27. pii: a031989.

Goumans MJ, Ten Dijke P. TGF-β Signaling in Control of Cardiovascular Function. Cold Spring Harb Perspect Biol. 2017 Mar 27. pii: a022210.

Gorter TM, Verschuuren EAM, van Veldhuisen DJ, Hoendermis ES, Erasmus ME, Bogaard HJ, Vonk Noordegraaf A, Berger RMF, van Melle JP, Willems TP. Right ventricular recovery after bilateral lung transplantation for pulmonary arterial hypertension. Interact Cardiovasc Thorac Surg. 2017 Jun 1;24(6):890-897. doi: 10.1093/icvts/ivx025.

Hansen MS, Andersen A, Holmboe S, Schultz JG, Ringgaard S, Simonsen U, Happé C, Bogaard HJ, Nielsen-Kudsk JE. Levosimendan prevents and reverts right ventricular failure in experimental pulmonary arterial hypertension. J Cardiovasc Pharmacol. 2017 Jun 19. doi: 10.1097/FJC.0000000000000508. [Epub ahead of print]

Kojonazarov B, Novoyatleva T, Boehm M, Happe C, Sibinska Z, Tian X, Sajjad A, Luitel H, Posern G, Evans SM, Grimminger F, Ghofrani HA, Weissmann N, Bogaard HJ, Seeger W, Schermuly RT. p38 MAPK Inhibition Improves Heart Function in Pressure Loaded Right Ventricular Hypertrophy. Am J Respir Cell Mol Biol. 2017 Jun 28. doi: 10.1165/rcmb.2016-0374OC. [Epub ahead of print]

van de Veerdonk MC, Huis In T Veld AE, Marcus JT, Westerhof N, Heymans MW, Bogaard HJ, Vonk-Noordegraaf A. Upfront combination therapy reduces right ventricular volumes in pulmonary arterial hypertension. Eur Respir J. 2017 Jun 29;49(6). pii: 1700007. doi: 10.1183/13993003.00007-2017. Print 2017 Jun.

Chen X, Orriols M, Walther FJ, Laghmani EH, Hoogeboom AM, Hogen-Esch ACB, Hiemstra PS, Folkerts G, Goumans MTH, Ten Dijke P, Morrell NW, Wagenaar GTM. Bone Morphogenetic Protein 9 Protects against Neonatal Hyperoxia-Induced Impairment of Alveolarization and Pulmonary Inflammation. Front Physiol. 2017 Jul 13;8:486. doi: 10.3389/fphys.2017.00486.

Orriols M, Gomez-Puerto MC, Ten Dijke P. BMP type II receptor as a therapeutic target in pulmonary arterial hypertension. Cell Mol Life Sci. 2017 Aug;74(16):2979-2995

de Wijs-Meijler DP, Duncker DJ, Tibboel D et al. Oxidative injury of the pulmonary circulation in the perinatal period: Short- and long-term consequences for the human cardiopulmonary system. Pulm Circ 2017;7:55-66

Hulshof HG, van Dijk AP, George KP et al. Echocardiographic-Derived Strain-Area Loop of the Right Ventricle is Related to Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension. JACC Cardiovasc Imaging 2017

Merkus D, Schermuly RT. Farnesylation of RhoB: the cancer hypothesis of pulmonary hypertension revisited. Cardiovasc Res 2017;113:249-250

Sorop O, Olver TD, van de Wouw J et al. The microcirculation: a key player in obesity-associated cardiovascular disease. Cardiovasc Res 2017

da Silva Gonçalves Bos D, van der Bruggen CE, Kurakula K, Sun XQ, Casali KR, Casali AG, Rol N, Szulcek R, dos Remedios C, Guignabert C, Tu L, Dorfmüller P, Humbert M, Wijnker PJ, Kuster DW, van der Velden J, Goumans MJ, Bogaard HJ, Vonk-Noordegraaf A, Handoko ML, de Man FS. Contribution of impaired parasympathetic activity to right ventricular dysfunction and pulmonary vascular remodeling in pulmonary arterial hypertension. Circulation 2017: in press

van der Feen DE, Bartelds B, de Boer RA, Berger RM. Pulmonary arterial hypertension in congenital heart disease: translational opportunities to study the reversibility of pulmonary vascular disease. Eur Heart J. 2017 Feb 23. doi: 10.1093/eurheartj/ehx034. [Epub ahead of print]

Bossers G, Hagdorn Q, Berger RM, Bartelds B. Experimental volume loading of the right ventricle. Eur J Heart Failure (2017, accepted)

Gorter TM, Verschuuren EAM, van Veldhuisen DJ, Hoendermis ES, Erasmus ME, Bogaard HJ, Vonk Noordegraaf A, Berger RMF, van Melle JP, Willems TP. Right ventricular recovery after bilateral lung transplantation for pulmonary arterial hypertension. Interact Cardiovasc Thorac Surg. 2017 Jun 1;24(6):890-897. doi: 10.1093/icvts/ivx025.

Ploegstra MJ, Brokelman JG, Roos-Hesselink JW, Douwes JM, van Osch-Gevers LM, Hoendermis ES, van den Bosch AE, Witsenburg M, Bartelds B, Hillege HL, Berger RM. Pulmonary arterial stiffness indices assessed by intravascular ultrasound in children with early pulmonary vascular disease: prediction of advanced disease and mortality during 20-year follow-up. Eur Heart J Cardiovasc Imaging. 2017 Mar 6. doi: 10.1093/ehjci/jex015. [Epub ahead of print]

Leberkühne LJ, Ploegstra MJ, Douwes JM, Bartelds B, Roofthooft MT, Hillege HL, Berger RM. Serially Measured Uric Acid Levels Predict Disease Severity and Outcome in Pediatric Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2017 Feb 1;195(3):401-404. doi: 10.1164/rccm.201606-1152LE. No abstract available.

ABSTRACTS, POSTERS AND PRESENTATIONS PHAEDRA

Harm Jan Bogaard

Oral presentation at University of Minnesota, dept of Cardiology Grand Rounds (Minneapolis, USA, May 26th): “The long road towards precision medicine in pulmonary hypertension”

Oral presentation at American Thoracic Society 2017 (Washington DC): “Pure Adrenaline: Role for Targeting the Sympathetic Nervous System in RV Failure? “

Oral presentation at Virginia Commonwealth University, Wright Center Clinical and Translational Research Seminar (Richmond, USA, May 20th 2017): “Right ventricular pulmonary artery interaction in left-sided heart failure”

Oral presentation at Pulmonary Vascular Research Institute (Miami, USA, January 27th 2017): “RV failure in PAH is initiated by RV ischemia – Pro”

Catalina Gomez-Puerto

Poster presentation at Congress of the Netherlands’ Heart Institute (Utrecht, the Netherlands, 29^th June 2017): “Releasing the pressure: Towards reversing pulmonary arterial hypertension with manganic porphyrin complex MnTBAP”

Poster presentation at FASEB Conference (Lisbon, Portugal, 9^th July 2018): “Releasing the pressure: Towards reversing pulmonary arterial hypertension with manganic porphyrin complex MnTBAP” 

Anna Huis in ‘t Veld

Poster discussion presentation at ATS, Washington, USA, May 2017: “Upfront combination therapy reduces right ventricular volumes in patients with PAH”

Oral presentation at ACS symposium, Amsterdam, Netherlands, July 2017: “Upfront combination therapy reduces right ventricular volumes in patients with PAH”

Oral presentation at ERS congress, Milan, Italy, September 2017: “Goal orientated strategy to preserve right ventricular ejection fraction trial: Results

Gonzalo Sanchez-Duffhues

Oral presentation at European Society of Vascular Surgery Congress (Leiden, the Netherlands, May 2017): “Inflammation-induced EndMT facilitates endothelial calcification” 

Denielli da Silva Goncalves Bos

Oral presentation at THALYS meeting, Brussels, Belgium, Oct 2016: “Parasympathetic Nervous System Stimulation By Pyridostigmine Improves Survival And Cardiac Function In Experimental Pulmonary Arterial Hypertension”

Oral presentation at Annual ACS (Amsterdam Cardiovascular Sciences) Symposium, Oosterkerk, Amsterdam, Oct 2016: “Parasympathetic Nervous System Stimulation by

Pyridostigmine Improves Survival and Cardiac Function in Experimental Pulmonary Arterial Hypertension”

Poster presentation at ATS, San Francisco, USA, May, 2016: “Parasympathetic Nervous System Stimulation by Pyridostigmine Improves Survival and Cardiac Function in Experimental Pulmonary Arterial Hypertension”

Robert Szulcek

Poster presentation at 11th PVRI annual world congress, Miami, FL, USA. January 2017: “Endothelial response to cytokine stimulation is disturbed in Pulmonary Arterial Hypertension: Cilium length as a functional marker for dysregulated immunity”

Oral presentation at International Vascular Biology Meeting (IVBM), Boston, MA, USA. October 2016: “Supra-physiological shear stress unveils heterogeneity in the endothelium of patients with Pulmonary Arterial Hypertension”

Sun Xiaoqing

Poster presentation at AHA conference, New Orleans, USA, November 2016: ” 6-mercaptopurine Reduces Progression of Experimentally Induced Pulmonary Arterial Hypertension by Dampening Inflammation and Inhibition of Proliferation”

Oral presentation at ERS conference, Milan, Italy, September 2017:” The effect of 6-Mercaptopurine treatment on experimentally induced pulmonary arterial hypertension”

Acknowledgements
See Agreement 7.2 and 7.3
7.2. Alleen de wetenschappelijke publicaties waarin de resultaten van het Onderzoeksproject worden gepubliceerd en waarin staat vermeld: “Dit Onderzoek maakt deel uit van het CVON, een initiatief van de Hartstichting, NFU, KNAW en NWO/ZonMW” of “We acknowledge the support from the Netherlands CardioVascular Research Initiative; the Dutch Heart Foundation, Dutch Federation of University Medical Centres, the Netherlands Organisation for Health Research and Development and the Royal Netherlands Academy of Sciences” worden gebruikt voor het vaststellen en beoordelen van de wetenschappelijke kwaliteit en kwantiteit van het gesubsidieerde Onderzoeksproject.

7.3. De Onderzoekers zijn verplicht om tijdens alle voordrachten, (poster)presentaties en/of interviews die over het Onderzoeksproject worden gehouden, het CVON logo duidelijk te tonen, waarbij wordt vermeld: “Dit Onderzoek maakt deel uit van het CVON, een initiatief van de Hartstichting, NFU, KNAW en NWO/ZonMW” of “We gratefully acknowledge the support from the Netherlands CardioVascular Research Initiative”: the Dutch Heart Foundation, the Dutch Federation of University Medical Centres, the Netherlands Organisation for Health Research and Development and the Royal Netherlands Acaddemy of Sciences.”  In publicaties en op posters dient tevens het CVON nummer (2012-08) en Phaedra te worden vermeld. Voor alle presentaties dient het CVON-format te worden gebruikt.